Fluoxetine shows promise in improving visual acuity for adults with amblyopia
Fluoxetine treatment may offer a beneficial adjunctive approach for enhancing visual acuity in adults with amblyopia, according to a study.
A recent randomized clinical trial evaluated the impact of oral fluoxetine on visual acuity and visual-evoked potential (VEP) parameters in adults diagnosed with amblyopia, specifically anisometropic or strabismic types. Participants (N = 55) were assigned to either a fluoxetine group (20 mg daily) or a placebo group, alongside standard amblyopia treatments, including corrective glasses and patching, over 4 months.
The fluoxetine group experienced a significant improvement in mean logMAR visual acuity of 0.20, compared to a lesser improvement of 0.08 in the placebo group. The fluoxetine group’s final mean visual acuity score of 0.36 was better than the placebo group’s score of 0.43. Although N75 amplitude in VEP did not show significant changes in either group, the fluoxetine group displayed a significant improvement in N135 latency from baseline.
Reference
Mirmohammadsadeghi A, Mousavi A, Akbari MR, et al. Fluoxetine as a possible treatment for adult amblyopia: results of a double-blind, randomized, placebo-controlled trial. J AAPOS. 2024;104009. doi: 10.1016/j.jaapos.2024.104009. Epub ahead of print. PMID: 39304030.
